MitoRx Therapeutics

The company develops mitochondrial-targeted small molecule therapeutics, specifically its lead asset MTRX31, to treat metabolically unhealthy obesity and insulin resistance. Its approach focuses on restoring metabolic flexibility and rebalancing fat and carbohydrate oxidation to eliminate ectopic fat from organs without suppressing appetite. The treatment aims to provide durable weight loss and reduce the risk of associated conditions such as type 2 diabetes, MASLD, and cardiovascular disease.